KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Treasury Shares (2016 - 2025)

Teva Pharmaceutical Industries' Treasury Shares history spans 17 years, with the latest figure at $4.1 billion for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares changed 0.0% year-over-year to $4.1 billion, compared with a TTM value of $4.1 billion through Dec 2025, changed 0.0%, and an annual FY2025 reading of $4.1 billion, changed 0.0% over the prior year.
  • Treasury Shares for Q4 2025 was $30.5 million at Teva Pharmaceutical Industries, down from $106.0 million in the prior quarter.
  • The five-year high for Treasury Shares was $107.0 million in Q4 2024, with the low at $24.4 million in Q4 2021.
  • Average Treasury Shares over 5 years is $91.0 million, with a median of $106.0 million recorded in 2021.
  • Biggest YoY gain for Treasury Shares was 0.0% in 2021; the steepest drop was 0.0% in 2021.
  • Tracing TEVA's Treasury Shares over 5 years: stood at $4.1 billion in 2021, then changed by 0.0% to $4.1 billion in 2022, then changed by 0.0% to $4.1 billion in 2023, then changed by 0.0% to $4.1 billion in 2024, then changed by 0.0% to $4.1 billion in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Treasury Shares are $4.1 billion (Q4 2025), $4.1 billion (Q3 2025), and $4.1 billion (Q2 2025).